Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (10245)	1/22/2010 4:08:49 PM
From: steve kammerer	of 10345

Well, Glad to hear about this for MS patients but what an interesting few years with a drug stock soaring and crashing 3 times. Such potential, such disappointment. FDA OKs Ampyra To Improve Walking In Adults With Multiple SclerosisFont size: A \| A \| A3:57 PM ET 1/22/10 \| Dow Jones RELATED QUOTES 4:00 PM ET 1/22/10 Symbol Last % Chg ACOR 28.12 9.76% ELN 8.04 2.29% Real time quote. By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The U.S. Food and Drug Administration Friday approved a new drug from Acorda Therapeutics Inc. (ACOR) to improve walking in patients with multiple sclerosis. The FDA said the drug, Ampyra, is the first drug approved to improve walking in MS patients. The agency said clinical trials showed patients treated with Ampyra had faster walking speeds than those treated with a placebo or fake pill. Multiple sclerosis is a progressive disease that involves damage to nerves controlling muscles and vision; it affects about 400,000 Americans. The condition causes the body's immune system to eat away at the protective covering of the nerves, or myelin, which disrupts the electrical signals between the brain and the rest of the body. Ampyra is designed to help the body's electric signals pass through by blocking potassium ions that leak from the damaged nerves. The FDA said the product will be manufactured under licenses from Elan Corp. PLC (ELN) of Dublin, Ireland, and distributed by Acorda, Hawthorne, N.Y. Acord shares recently rose 9% to $28. -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next